December 16, 2024

Cosibelimab-ipdl Approved by FDA for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

The U.S. Food and Drug Administration (FDA) recently approved cosibelimab-ipdl (Unloxcyt), a PD-L1–blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell carcinoma w...

The ASCO Post

December 12, 2024

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

A recent study published in JAMA Dermatology revealed the significant efficacy of nemolizumab in reducing pruritus and skin lesions in patients with moderate to severe prurigo nodularis.

Conexiant

December 11, 2024

Combo Induces HBsAg Loss in HBV

A recent study found that a combination therapy in chronic hepatitis B patients with virologic suppression showed promising results in achieving HBsAg loss, but emphasized the need for longer follow-up to assess durability and potential side effects.

Conexiant

December 11, 2024

Pro-inflammatory Diet May Weaken Women's Bones

Study finds that hypertensive women consuming pro-inflammatory diets are at an increased risk of osteopenia due to lower lumbar vertebrae bone mineral density.

Conexiant

December 11, 2024

Vitamin D Tied to ICU Survival

A study on ICU patients with sepsis-associated acute kidney injury revealed a 41% lower risk of in-hospital mortality with vitamin D supplementation, highlighting the potential benefits of this approach. Source: Frontiers in Medicine

Conexiant

December 10, 2024

ASCVD Risk Elevated in Cutaneous Lupus

Recent study in JAMA Dermatology shows patients with cutaneous lupus erythematosus have a 72% higher risk of developing atherosclerotic cardiovascular disease, emphasizing the need for targeted screening and management.

Conexiant

December 10, 2024

Biomarkers in Familial Mediterranean Fever: Therapy Insights

A recent study on familial Mediterranean fever revealed that nearly 56% of heterozygous patients who stopped colchicine therapy sustained remission with lower levels of specific biomarkers, highlighting the potential of personalized treatment for FMF patients.

Conexiant

December 09, 2024

Do SGLT2i, GLP-1 RAs Cut Pneumonia, Sepsis Risk?

In the largest real-world study to date, GLP-1 receptor agonists reduced pneumonia risk by 40% in type 2 diabetes patients.

Conexiant

December 09, 2024

UV Radiation, Virus Key Drivers of Merkel Cell Carcinoma Cases

A recent study in JAMA Dermatology reveals that over 65% of Merkel cell carcinoma cases in the US may be attributed to ultraviolet radiation exposure, while 63.8% may be linked to the Merkel cell polyomavirus.

Conexiant